5h-[1,3]Thiazolo[3,2-a]pyrimidine | 275-26-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5h-[1,3]Thiazolo[3,2-a]pyrimidine
• CAS: 275-26-3
• 化学式: C₆H₆N₂S
• 分子量: 138.19
• InChiKey: CDUYCVWBLGEWSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20170158680A1

  公开（公告）日：2017-06-08

  The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

  本发明提供了一种由公式（I）表示的杂环化合物，其立体异构体，或其药用可接受的盐，其药物组合物，以及它们用于制备预防或治疗中枢神经系统疾病的药物。
• [EN] IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS<br/>[FR] DÉRIVÉS D'IMIDAZOLINE UTILISÉS EN TANT QUE MODULATEURS DE CXCR4
  申请人：UNIV PARIS

  公开号：WO2020201096A1

  公开（公告）日：2020-10-08

  The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., lupus erythematosus, dermatomyositis or rheumatoid arthritis.

  本发明提供了化合物的新结构（I）及含有这些化合物的药物组合物。式（I）化合物可以作为CXCR4调节剂，特异性靶向CXCR4小口袋，并且进一步发现能够抑制免疫细胞中炎症细胞因子的产生，使得这些化合物在治疗中具有极大的优势，特别适用于治疗或预防炎症性疾病、自身免疫性疾病、自身炎症性疾病或干扰素病，例如红斑狼疮、皮肌炎或类风湿性关节炎。
• Use of derivatives of 3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine or of 3-oxo-2,3-dihydro-5H-imidazolo[3,2-a]pyrimidine for the preparation of pharmaceutical compositions intended for the treatment of cancer
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：EP2000140A1

  公开（公告）日：2008-12-10

  The present invention is related to the use of a compound of formula (I) for the preparation of a pharmaceutical composition intended for the treatment of cancer and in particular for the treatment of the prostate cancer, hepatocarcinomas, head and neck cancer, oesophagus cancer, thyroid gland cancer or non-hodgkinian lymphomas and some new compounds and pharmaceutical compositions containing them.

  本发明涉及使用式（I）的化合物制备用于治疗癌症的药物组合物，特别是用于治疗前列腺癌、肝癌、头颈癌、食管癌、甲状腺癌或非霍奇金淋巴瘤的药物组合物，以及一些新的化合物和含有它们的药物组合物。
• Polycyclic thiazol-2-ylidene amines, processes for their preparation and their use as medicaments
  申请人：——

  公开号：US20010011096A1

  公开（公告）日：2001-08-02

  The invention relates to polycyclic thiazolidin-2-ylidene amines and their physiologically tolerated salts and physiologically functional derivatives. Polycyclic thiazolidin-2-ylidene amines of the formula I, 1 in which the radicals have the stated meanings, and their physiologically tolerated salts and processes for their preparation are described. The compounds are suitable, for example as anorectics and in the treatment or prophylaxis of type II diabetes.

  本发明涉及多环噻唑啉-2-基亚胺及其生理耐受盐和生理功能衍生物。本发明描述了式I中的多环噻唑啉-2-基亚胺，其中基团具有所述的含义，以及其生理耐受盐和制备过程。该化合物适用于例如作为食欲抑制剂以及用于治疗或预防II型糖尿病。
• Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer
  申请人：Block Howard Michael

  公开号：US20070287703A1

  公开（公告）日：2007-12-13

  Compounds which possess Eg5 inhibitory activity and are useful for their anti-cell-proliferation (such as anti-cancer) activity and thus in methods of treatment of the human or animal body are described.

  本文描述了具有Eg5抑制活性并用于其抗细胞增殖（如抗癌）活性以及人体或动物体治疗方法中有用的化合物。